Surge Therapeutics Raises $26M Series A Financing To Accelerate Development Of Intraoperative Immunotherapy To Improve Survival Outcomes Post-Surgery
Surge Therapeutics Raises $26M Series A Financing To Accelerate Development Of Intraoperative Immunotherapy To Improve Survival Outcomes Post-Surgery
10/17/22, 12:00 PM
Location
cambridgeMoney raised
$26 million
Industry
biotechnology
health care
therapeutics
Round Type
series a
SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Cancer Research Institute. The funds will be used to accelerate development of the SURGETM intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.
Company Info
Location
cambridge, maryland, united states
Additional Info
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.
Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.